CVKD ▲ +3.9% - Cadrenal Therapeutics, Inc. $CVKD - Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia Cadrenal Therapeutics shares rose 3.9% following the company's announcement of a positive outcome from an FDA Type D meeting regarding its Phase 3 registration study for CAD-1005, a treatment for heparin-induced thrombocytopenia. The favorable meeting feedback suggests the company's clinical development pathway has regulatory support, potentially clearing the way for the pivotal trial needed to advance the candidate toward approval. 31-AUG-2026 08:00 AM ET